Toxoplasmosis is an opportunistic infection caused by the protozoan parasite Toxoplasma gondii. T. gondii is widespread globally and causes severe diseases in individuals with impaired immune defences as well as congenitally infected infants. The high prevalence rate in some parts of the world such as South America and Africa, coupled with the current drug treatments that trigger hypersensitivity reactions, makes the development of immunotherapeutics intervention a highly important research priority. Immunotherapeutics strategies could either be a vaccine which would confer a pre-emptive immunity to infection, or passive immunization in cases of disease recrudescence or recurrent clinical diseases. As the severity of clinical manifestations is often greater in developing nations, the development of well-tolerated and safe immunotherapeutics becomes not only a scientific pursuit, but a humanitarian enterprise. In the last few years, much progress has been made in vaccine research with new antigens, novel adjuvants, and innovative vaccine delivery such as nanoparticles and antigen encapsulations. A literature search over the past 5 years showed that most experimental studies were focused on DNA vaccination at 52%, followed by protein vaccination which formed 36% of the studies, live attenuated vaccinations at 9%, and heterologous vaccination at 3%; while there were few on passive immunization. Recent progress in studies on vaccination, passive immunization, as well as insights gained from these immunotherapeutics is highlighted in this review.
Citations
Citations to this article as recorded by
In silico analysis and structural vaccinology prediction of Toxoplasma gondii ROP41 gene via immunoinformatics methods as a vaccine candidate Masoumeh Asadi, Ali Dalir Ghaffari, Fatemeh Mohammadhasani Current Research in Translational Medicine.2025; 73(1): 103475. CrossRef
Toxoplasma gondii (GRA10): A Closer Glance Into Immunogenic and Biochemical Characteristics Using In Silico Approach Mahdi Khadem Mohammadi, Ali Dalir Ghaffari Parasite Immunology.2025;[Epub] CrossRef
Design and immunological evaluation of a multi-epitope vaccine candidate against Toxoplasma gondii incorporating MIC13, GRA1, and SAG1 antigens in BALB/c mice Zahra Hosseininejad, Ahmad Daryani, Mahdi Fasihi-Ramandi, Hossein Asgarian-Omran, Tooran Nayeri, Samira Dodangeh, Afsaneh Amouei, Javad Javidnia, Sabah Mayahi, Shahabeddin Sarvi, Sargis A. Aghayan Food and Waterborne Parasitology.2025; 40: e00269. CrossRef
Effective factors in the pathogenesis of Toxoplasma gondii Tooran Nayeri, Shahabeddin Sarvi, Ahmad Daryani Heliyon.2024; 10(10): e31558. CrossRef
Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine against Toxoplasma gondii Carina Brito, Camila Lourenço, Joana Magalhães, Salette Reis, Margarida Borges Vaccines.2023; 11(4): 733. CrossRef
Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases Grzegorz Król, Kamila Fortunka, Michał Majchrzak, Ewelina Piktel, Paulina Paprocka, Angelika Mańkowska, Agata Lesiak, Maciej Karasiński, Agnieszka Strzelecka, Bonita Durnaś, Robert Bucki Pathogens.2023; 12(6): 838. CrossRef
Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status Esam S. Al-Malki Saudi Journal of Biological Sciences.2021; 28(1): 962. CrossRef
Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection Nadia Arcon, Mariano S. Picchio, Ignacio M. Fenoy, Rosalía E. Moretta, Ariadna S. Soto, Matías D. Perrone Sibilia, Vanesa R. Sánchez, Cecilia A. Prato, María Virginia Tribulatti, Alejandra Goldman, Valentina Martin Vaccine.2021; 39(6): 933. CrossRef
Evaluation of immunogenicity and protection of the Mic1-3 knockout Toxoplasma gondii live attenuated strain in the feline host Delphine Le Roux, Vitomir Djokic, Solen Morisse, Clément Chauvin, Vanessa Doré, Anne-Claire Lagrée, Déborah Voisin, Yohan Villain, Aurélie Grasset-Chevillot, Fanny Boursin, Chunlei Su, Sébastien Perrot, Isabelle Vallée, Edouard Seche, Radu Blaga Vaccine.2020; 38(6): 1457. CrossRef
A Review on the Prevalence of Toxoplasma gondii in Humans and Animals Reported in Malaysia from 2008–2018 Mohammed Nasiru Wana, Mohamad Aris Mohd Moklas, Malaika Watanabe, Norshariza Nordin, Ngah Zasmy Unyah, Sharif Alhassan Abdullahi, Ashraf Ahmad Issa Alapid, Tijjani Mustapha, Rusliza Basir, Roslaini Abd. Majid International Journal of Environmental Research and Public Health.2020; 17(13): 4809. CrossRef
In Silico Prediction of T and B Cell Epitopes of SAG1-Related Sequence 3 (SRS3) Gene for Developing Toxoplasma gondii Vaccine Abolfazl Mirzadeh, Geita Saadatnia, Majid Golkar, Jalal Babaie, Samira Amiri, Asiyeh Yoosefy Archives of Clinical Infectious Diseases.2020;[Epub] CrossRef
Treatment of toxoplasmosis: Current options and future perspectives Neda Konstantinovic, Hélène Guegan, Tijana Stäjner, Sorya Belaz, Florence Robert-Gangneux Food and Waterborne Parasitology.2019; 15: e00036. CrossRef
In silico analysis and expression of a novel chimeric antigen as a vaccine candidate against Toxoplasma gondii Samira Dodangeh, Mahdi Fasihi-Ramandi, Ahmad Daryani, Reza Valadan, Shahabeddin Sarvi Microbial Pathogenesis.2019; 132: 275. CrossRef
Evaluation of Anti-Toxoplasma gondii Immune Responses in BALB/c Mice Induced by DNA Vaccines Encoding Surface Antigen 1 (SAG1) and 3 (SAG3) H. Sobati, A. Dalimi, B. Kazemi, F. Ghaffarifar Molecular Genetics, Microbiology and Virology.2019; 34(1): 59. CrossRef
The course of infection with Toxoplasma gondii RH strain in mice pre-vaccinated with gamma irradiated tachyzoites Ahmed M. Gomaa, Nora L. El-Tantawy, Aliaa M. Elsawey, Ramy A. Abdelsalam, Manar S. Azab Experimental Parasitology.2019; 205: 107733. CrossRef
Plant-derived chimeric antibodies inhibit the invasion of human fibroblasts byToxoplasma gondii Sherene Swee Yin Lim, Kek Heng Chua, Greta Nölke, Holger Spiegel, Wai Leong Goh, Sek Chuen Chow, Boon Pin Kee, Rainer Fischer, Stefan Schillberg, Rofina Yasmin Othman PeerJ.2018; 6: e5780. CrossRef
Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection Mona Roozbehani, Reza Falak, Mohsen Mohammadi, Andrew Hemphill, Elham Razmjou, Ahmad reza Meamar, Leila Masoori, Majid Khoshmirsafa, Maryam Moradi, Mohammad Javad Gharavi Vaccine.2018; 36(41): 6124. CrossRef
Synergic in vitro combinations of artemisinin, pyrimethamine and methylene blue against Neospora caninum Luiz Miguel Pereira, Gabriela de Luca, Nathália de Lima Martins Abichabki, Cássia Mariana Bronzon da Costa, Ana Patrícia Yatsuda Veterinary Parasitology.2018; 249: 92. CrossRef
Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice Mariano S. Picchio, Vanesa R. Sánchez, Nadia Arcon, Ariadna S. Soto, Matías Perrone Sibilia, María de los Angeles Aldirico, Mariela Urrutia, Rosalía Moretta, Ignacio M. Fenoy, Alejandra Goldman, Valentina Martin Experimental Parasitology.2018; 185: 62. CrossRef
Calcium-dependent protein kinases are potential targets forToxoplasma gondiivaccine Masoud Foroutan, Fatemeh Ghaffarifar Clinical and Experimental Vaccine Research.2018; 7(1): 24. CrossRef
Recent progress in microneme-based vaccines development againstToxoplasma gondii Masoud Foroutan, Leila Zaki, Fatemeh Ghaffarifar Clinical and Experimental Vaccine Research.2018; 7(2): 93. CrossRef
A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006–2016) Mahbobeh Montazeri, Mehdi Sharif, Shahabeddin Sarvi, Saeed Mehrzadi, Ehsan Ahmadpour, Ahmad Daryani Frontiers in Microbiology.2017;[Epub] CrossRef
The genome of the protozoan parasite Cystoisospora suis and a reverse vaccinology approach to identify vaccine candidates Nicola Palmieri, Aruna Shrestha, Bärbel Ruttkowski, Tomas Beck, Claus Vogl, Fiona Tomley, Damer P. Blake, Anja Joachim International Journal for Parasitology.2017; 47(4): 189. CrossRef
Immunization with Toxoplasma gondii aspartic protease 3 increases survival time of infected mice Guanghui Zhao, Xiaojie Song, Xiangnan Kong, Ning Zhang, Shaoling Qu, Wei Zhu, Yanyan Yang, Qian Wang Acta Tropica.2017; 171: 17. CrossRef
Vaccination with recombinant adenovirus expressing multi-stage antigens ofToxoplasma gondiiby the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes Ting Wang, Huiquan Yin, Yan Li, Lingxiao Zhao, Xiahui Sun, Hua Cong Parasite.2017; 24: 12. CrossRef
An evaluation of a recombinant multiepitope based antigen for detection of Toxoplasma gondii specific antibodies Khalid Hajissa, Robaiza Zakaria, Rapeah Suppian, Zeehaida Mohamed BMC Infectious Diseases.2017;[Epub] CrossRef
Vaccination against parasites – status quo and the way forward Anja Joachim Porcine Health Management.2016;[Epub] CrossRef
Immunization of Wistar female rats with 255-Gy-irradiated Toxoplasma gondii: Tissue parasitic load and lactogenic quantification Lucilene Granuzzio Camossi, Felipe Fornazari, Virgínia Bodelão Richini-Pereira, Rodrigo Costa da Silva, Daniel Fontana Ferreira Cardia, Helio Langoni Experimental Parasitology.2015; 154: 163. CrossRef
Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection Vanesa R. Sánchez, Ignacio M. Fenoy, Mariano S. Picchio, Ariadna S. Soto, Nadia Arcon, Alejandra Goldman, Valentina Martin Acta Tropica.2015; 150: 159. CrossRef
Seroprevalence of <i>Toxoplasma gondii</i> Among Primary School Children in Shandong Province, China Ke-Sheng Xin, Hui Liu, Hong-Bing Wang, Zong-Liang Yao The Korean Journal of Parasitology.2015; 53(4): 489. CrossRef
In Vitro
and
In Vivo
Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum
Pablo Winzer, Joachim Müller, Adriana Aguado-Martínez, Mahbubur Rahman, Vreni Balmer, Vera Manser, Luis Miguel Ortega-Mora, Kayode K. Ojo, Erkang Fan, Dustin J. Maly, Wesley C. Van Voorhis, Andrew Hemphill Antimicrobial Agents and Chemotherapy.2015; 59(10): 6361. CrossRef
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity Andrew J. Neville, Sydney J. Zach, Xiaofang Wang, Joshua J. Larson, Abigail K. Judge, Lisa A. Davis, Jonathan L. Vennerstrom, Paul H. Davis Antimicrobial Agents and Chemotherapy.2015; 59(12): 7161. CrossRef
First
Prev
